Oxford Cannabinoid Technologies
Oxford Cannabinoid Technologies · page 2
- Medical
UK Medical Cannabis Industry Gathers Momentum Amid Numerous Research Milestones
The UK’s National Health Service (NHS) Research Ethics Committee this week approved the full-scale rollout of a new clinical trial into medical cannabis and non-cancer chronic pain.
- Markets & Stocks
OCT Announces Potential New ‘First In Class’ Immunotherapy Treatment, Kanabo Stock Jumps On New Deal, Intercure Leaves TSX
Oxford Cannabinoid Technologies [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”OCTP.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Oxford Cannabinoid Technologies announced this week that it had identified a potential ‘first in class’ immunotherapy treatment for solid tumours.
- Press releases
Oxford Cannabinoid Technologies Announces Expansion Into Oncology
OCTP, the pharmaceutical company developing prescription cannabinoid medicines, is formally expanding its research and development strategy into oncology having identified a potential “first in class” immunotherapy agent for the treatment of solid tumours.
- Markets & Stocks
OCT Secures MHRA Approval For Clinical Trials, Cantourage Posts First Profits, & More From DanCann Pharma
Oxford Cannabinoid Technologies [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”OCTP.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] The London Stock Exchange listed pharmaceutical cannabis company announced yesterday that it has at last secured MHRA approval for its Phase 1 Clinical Trials for its lead compound.
